Combination of PARP and DNA methylation inhibitors as a potential personalized therapy for SETD2-mutated clear-cell renal cancers. | Transl Androl Urol;13(7): 1315-1318, 2024 Jul 31. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Combination of PARP and DNA methylation inhibitors as a potential personalized therapy for SETD2-mutated clear-cell renal cancers.

Shahini, Ali; Riazalhosseini, Yasser.

Affiliation

Shahini A; Department of Human Genetics, McGill University, Montreal, Canada.
Riazalhosseini Y; Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, Quebec, Canada.

Transl Androl Urol ; 13(7): 1315-1318, 2024 Jul 31.

Article in En | MEDLINE | ID: mdl-39100825

Key words

DNA methylation; PARP inhibitors (PARPi); SETD2 mutation; renal cell carcinoma

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Androl Urol Year: 2024 Document type: Article Affiliation country: Canadá Country of publication: China

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Androl Urol Year: 2024 Document type: Article Affiliation country: Canadá Country of publication: China